Scholarlink

Background <p>High-fat diets (HFDs) play a central role in the onset and progression of metabolic syndrome. This study investigated the protective effects of silymarin (SM)-loaded phytosomal nanoparticles (SM-PNPs) against high-fat diet (HFD)-induced hepatic dysfunction and metabolic disorders, with emphasis on antioxidant and anti-inflammatory mechanisms.</p> Methods <p>Sixty rats were randomly divided into six groups: control, SM-treated (200&#xa0;mg/kg body weight), SM-PNPs-treated (200&#xa0;mg/kg body weight), HFD-treated, and two combination groups receiving HFD along with either SM or SM-PNPs (200&#xa0;mg/kg body weight) for 5 weeks during the final phase of a 20-week HFD feeding period.</p> Results <p>SM-PNPs therapy demonstrated stronger hepatoprotective activity than unencapsulated SM. It significantly improved metabolic abnormalities, including insulin resistance, dyslipidemia, and hepatopathy in HFD-fed rats. Moreover, SM-PNPs ameliorated HFD-induced alterations in fasting glucose and insulin levels and improved HOMA-IR indices, thereby restoring glucose homeostasis. Treatment also markedly reduced oxidative stress while enhancing the antioxidant defense system. RT-PCR analysis revealed significant downregulation of key inflammatory genes, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B (NF-κB), and inducible nitric oxide synthase (iNOS), along with a significant reduction in systemic inflammation, as indicated by decreased high-sensitivity C-reactive protein (hsCRP) levels, as well as apoptosis caspases activities. The in-silico analysis revealed significant interactions of SM with crucial proteins involved in regulating antioxidant defense and inflammatory pathways. Histopathological and ultrastructural examinations further supported these biochemical findings, showing that SM-PNPs attenuated hepatic steatosis, collagen deposition, and fibrosis.</p> Conclusions <p>SM-PNPs exert a significant protective effect against HFD-induced hepatic damage and metabolic disturbances and represent a promising therapeutic strategy for metabolic dysfunction-associated steatotic liver disease (MASLD), potentially due to improved solubility, bioavailability, and sustained release in the nanoparticle formulation.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Silymarin-loaded phytosomal nanoparticles mitigate dyslipidemia, oxidative damage, and hepatic injury in high-fat diet-induced metabolic dysfunction-associated steatotic liver disease in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Shahad W. Kattan,
  • Amany I. Almars,
  • Wajnat A. Tounsi,
  • Areej Ahmed Turkistani,
  • Ahmed M. Mohamed,
  • Mona M. Elghareeb,
  • Ekramy M. Elmorsy,
  • Shaymaa H.E. Ali

摘要

Background

High-fat diets (HFDs) play a central role in the onset and progression of metabolic syndrome. This study investigated the protective effects of silymarin (SM)-loaded phytosomal nanoparticles (SM-PNPs) against high-fat diet (HFD)-induced hepatic dysfunction and metabolic disorders, with emphasis on antioxidant and anti-inflammatory mechanisms.

Methods

Sixty rats were randomly divided into six groups: control, SM-treated (200 mg/kg body weight), SM-PNPs-treated (200 mg/kg body weight), HFD-treated, and two combination groups receiving HFD along with either SM or SM-PNPs (200 mg/kg body weight) for 5 weeks during the final phase of a 20-week HFD feeding period.

Results

SM-PNPs therapy demonstrated stronger hepatoprotective activity than unencapsulated SM. It significantly improved metabolic abnormalities, including insulin resistance, dyslipidemia, and hepatopathy in HFD-fed rats. Moreover, SM-PNPs ameliorated HFD-induced alterations in fasting glucose and insulin levels and improved HOMA-IR indices, thereby restoring glucose homeostasis. Treatment also markedly reduced oxidative stress while enhancing the antioxidant defense system. RT-PCR analysis revealed significant downregulation of key inflammatory genes, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B (NF-κB), and inducible nitric oxide synthase (iNOS), along with a significant reduction in systemic inflammation, as indicated by decreased high-sensitivity C-reactive protein (hsCRP) levels, as well as apoptosis caspases activities. The in-silico analysis revealed significant interactions of SM with crucial proteins involved in regulating antioxidant defense and inflammatory pathways. Histopathological and ultrastructural examinations further supported these biochemical findings, showing that SM-PNPs attenuated hepatic steatosis, collagen deposition, and fibrosis.

Conclusions

SM-PNPs exert a significant protective effect against HFD-induced hepatic damage and metabolic disturbances and represent a promising therapeutic strategy for metabolic dysfunction-associated steatotic liver disease (MASLD), potentially due to improved solubility, bioavailability, and sustained release in the nanoparticle formulation.

Graphical Abstract